filtered. The solvent was removed and the crude product was
purified by column chromatography on silica (toluene–AcOEt,
85 : 15). The product was obtained as a white solid (9.36 g,
14.0 mmol, 74% yield). Suitable crystals for X-ray analysis were
obtained as colourless blocks after slow diffusion of hexane
into a solution of the product in chloroform for a few days. 1H
NMR (CDCl3): 7.72 (d, J = 8.2, 4H), 7.64 (d, J = 8.2, 2H),
7.14–7.40 (m, 4H), 7.35 (d, J = 8.2, 4H), 7.28 (d, J = 8.2, 2H),
4.21 (s, 4H), 3.04 (t, 4H), 2.58 (t, 4H), 2.46 (s, 6H), 2.42 (s,
K2CO3 (52.24 g, 378 mmol) and 1,3-bis(bromomethyl)-benzene
(5.00 g, 18.9 mmol) yielded the product as a white solid (8.77 g,
8.25 mmol, 69% yield). Suitable crystals for X-ray analysis were
obtained as colorless blocks in the same manner as for L1–Ts3.
1H NMR (CDCl3): 7.76 (d, J = 8.3, 4H), 7.70 (d, J = 8.3, 4H),
7.64 (d, J = 8.3, 2H), 7.48 (d, J = 8.2, 2H), 7.36 (d, J = 8.3,
4H), 7.34 (d, J = 8.3, 4H), 7.24 (m, 1H), 7.17 (d, J = 8.5, 2H),
7.04 (s, 1H), 4.25 (s, 4H), 3.18 (b, 4H), 3.13 (b, 4H), 3.02 (b,
1
8H), 2.47 (s, 6H), 2.46 (s, 3H), 2.45 (s, 6H); 13C-{ H} NMR
1
3H); 13C-{ H} NMR (CDCl3): 142.55, 142.35, 134.93, 134.45,
(CDCl3): 144.49, 144.21, 144.14, 136.95, 135.89, 135.31, 134.14,
130.32, 130.01, 128.68, 128.60, 128.00, 127.89, 127.82, 53.91,
51.17, 50.26, 49.99, 47.75, 21.97; MS m/z (FAB) 1063 ([M +
H]+); anal. calcd for C51H59S5O10N5: C, 57.66%; H, 5.60%; N,
6.59%. Found: C, 57.81%; H, 5.73%; N, 6.70%.
133.83, 129.87, 129.52, 129.07, 128.71, 128.60, 125.96, 125.88,
53.19, 52.22, 49.17, 46.06, 20.32, 20.29; MS m/z (FAB) 668
([M + H]+); anal. calcd for C33H37S3O6N3: C, 59.37%; H, 5.59%;
N, 6.29%. Found: C, 59.50%; H, 5.47%; N, 6.26%.
N,Nꢀ,Nꢀꢀ-Tritosyl-2,6,10-triaza[11]metacyclophane (L2–Ts3).
By following a procedure similar to that described for
the synthesis of L1–Ts3, N,Nꢀ,Nꢀꢀ-tritosyl-1,5,9-triazanonane
(11.23 g, 18.9 mmol), K2CO3 (52.24 g, 378 mmol) and 1,3-
bis(bromomethyl)-benzene (5.00 g, 18.9 mmol) yielded the
product as a white solid (9.87 g, 14.2 mmol, 75% yield). Suitable
crystals for X-ray analysis were obtained as colorless blocks in
2,6,9,13-Tetraaza[14]metacyclophane (L3). A mixture of to-
sylated amine L3–Ts3 (2.00 g, 2.24 mmol), phenol (4.0 g,
42.50 mmol) and 60 mL of 48% aqueous HBr was stirred and
heated to reflux for 72 h. After cooling to rt, the mixture was
repeatedly washed with chloroform. The aqueous phase was
cooled to 0 ◦C and sodium hydroxide was added slowly until the
pH of the solution became at least 12. The product was extracted
in chloroform which was removed under a high vacuum to afford
the free amine as a waxy solid (0.32 g, 1.16 mmol, 52% yield).
Suitable cystals for X-ray analysis of the fluoride, chloride and
bromide salts of L3 were obtained in two ways: Either from a
solution of this material in the corresponding diluted acid after a
few days by slow evaporation or by slow diffusion of acetone into
a concentrated solution of the macrocycle in the corresponding
diluted acid. The species L3·3HClO4·HBr·H2O was synthesized
after a mixture of L3 and perchloric acid was accidentally treated
with fumes of hydrobromic acid inside a fume cubpoard (for
crystal data, see Table 2). Suitable cystals for X-ray analysis
of the free amine L3 were obtained by slow evaporation of a
concentrated solution of the compound in chloroform. 1H NMR
(CDCl3): 7.34 (s, 1H), 7.18 (t, J = 7.4, 1H), 7.04 (d, J = 7.6,
2H), 3.73 (s, 4H), 2.62–2.66 (m, 4H), 2.61 (s, 4H), 1.73 (s, b, 4H),
1
the same manner as for L1–Ts3. H NMR (CDCl3): 7.72 (d,
J = 8.2, 4H), 7.58 (d, J = 8.2, 2H), 7.14–7.47 (m, 4H), 7.35
(d, J = 8.2, 4H), 7.16 (d, J = 8.2, 2H), 4.18 (s, 4H), 3.07 (t,
J = 6.8, 4H), 2.86 (t, J = 7.3, 4H), 2.45 (s, 6H), 2.41 (s, 3H),
1
1.35 (m, 4H); 13C-{ H} NMR (CDCl3): 143.87, 143.53, 137.57,
135.59, 130.12, 129.93, 129.76, 129.71, 129.69, 129.24, 127.41,
127.27, 54.46, 47.97, 47.94, 29.34, 21.74, 21.68; MS m/z (FAB)
696 ([M + H]+); anal. calcd for C35H36S3O6N3: C, 60.42%; H,
5.94%; N, 6.04%. Found: C, 60.37%; H, 5.88%; N, 5.94%.
N,Nꢀ,Nꢀꢀ,Nꢀꢀꢀ-Tetratosyl-2,5,8,11-tetraaza[12]metacyclophane
(L4–Ts4). By following a procedure similar to that described
for the synthesis of L1–Ts3, N,Nꢀ,Nꢀꢀ,Nꢀꢀꢀ-tetratosyl-1,4,7,10-
tetraazadecane62 (14.42 g, 18.9 mmol), K2CO3 (52.24 g,
378 mmol) and 1,3-bis(bromomethyl)benzene (5.00 g,
18.9 mmol) yielded the product as a white solid (11.11 g,
12.9 mmol, 68% yield). Suitable crystals for X-ray analysis were
obtained as colorless blocks in the same manner as for L1–Ts3.
1H NMR (CDCl3): 7.75 (d, J = 8.2, 4H), 7.69 (d, J = 8.2, 4H),
7.11–7.38 (m, 4H), 7.37 (d, J = 8.2, 4H), 7.31 (d, J = 8.2, 4H),
4.13 (s, 4H), 2.98 (t, J = 5.3, 4H), 2.89 (t, J = 5.6, 4H), 2.68
1
1.60–1.67 (m, 4H); 13C-{ H} NMR (CDCl3): 140.78, 128.79,
127.70, 127.30, 54.48, 50.38, 50.00, 48.79, 29.87; HRMS calcd
for C16H29N4 [M]+ 277.2387, found 277.2363. Ligand L3 has
previously been prepared ina similar way.
2,5,8,11,14-Pentaaza[15]metacyclophane (L5). By following
a procedure similar to that described for the synthesis of L3, L5–
Ts5 (2.00 g, 1.88 mmol), phenol (4.0 g, 42.50 mmol) and 60 mL of
48% aqueous HBr afforded the product as a waxy solid (0.43 g,
1.47 mmol, 78% yield). Suitable cystals for X-ray analysis of
the chloride (two structures), bromide and iodide salts of the
1
(s, 4H), 2.47 (s, 6H), 2.44 (s, 6H); 13C-{ H} NMR (CDCl3):
144.37, 144.12, 137.03, 135.90, 134.80, 130.40, 130.25, 129.99,
129.31, 127.88, 127.81, 54.82, 50.15, 49.21, 48.28, 21.98, 21.97;
MS m/z (FAB) 865 ([M + H]+); anal. calcd for C42H48S4O8N4:
C, 58.31%; H, 5.59%; N, 6.48%. Found: C, 58.39%; H, 5.54%;
N, 6.43%.
1
macrocycle were obtained in a similar manner as for L3. H
NMR (CDCl3): 7.54 (s, 1H), 7.12 (t, J = 7.4, 1H), 7.00 (d, J =
N,Nꢀ,Nꢀꢀ,Nꢀꢀꢀ-Tetratosyl-2,6,9,13-tetraaza[14]metacyclophane
(L3–Ts4). By following a procedure similar to that described
for the synthesis of L1–Ts3, N,Nꢀ,Nꢀꢀ,Nꢀꢀꢀ-tetratosyl-1,5,8,12-
tetraazadodecane (14.95 g, 18.9 mmol), K2CO3 (52.24 g,
378 mmol) and 1,3-bis(bromomethyl)-benzene (5.00 g,
18.9 mmol) yielded the product as a white solid (11.98 g,
13.42 mmol, 71% yield). Suitable crystals for X-ray analysis
were obtained as colorless blocks in the same manner as
1
7.3, 2H), 3.73 (s, 4H), 2.65–2.76 (m, 16H), 2.32 (b, 5H); 13C-{ H}
NMR (CDCl3): 141.16, 128.26, 127.23, 126.84, 53.96, 49.65,
49.53, 49.52, 48.99; HRMS calcd for C16H30N5 [M]+ 292.2496,
found 292.2491.
2,5,8-Triaza[9]metacyclophane (L1). By following a proce-
dure similar to that described for the synthesis of L3, L1–Ts3
(2.00 g, 2.99 mmol), phenol (4.0 g, 42.50 mmol) and 60 mL of
48% aqueous HBr afforded the product as a waxy solid (0.40 g,
1.94 mmol, 65% yield). Suitable crystals for X-ray analysis of
this material were obtained by slow diffusion of n-hexane into
a solution of the compound in chloroform after a few days. 1H
NMR (CDCl3): 8.20 (s, 1H), 7.08 (t, J = 7.5, 1H), 6.95 (d, J =
7.3, 2H), 3.83 (s, 4H), 2.66 (t, J = 5.1, 4H), 2.45 (s, b, 3H), 2.06 (s,
1
for L1–Ts3. H NMR (CDCl3): 7.72 (d, J = 8.2, 4H), 7.65 (d,
J = 8.2, 4H), 7.11–7.54 (m, 4H), 7.37 (d, J = 8.2, 4H), 7.33
(d, J = 8.2, 4H), 4.17 (s, 4H), 3.11 (t, J = 7.2, 4H), 2.94 (t,
J = 7.0, 4H), 2.66 (s, 4H), 2.46 (s, 6H), 2.44 (s, 6H), 1.41 (m,
1
4H); 13C-{ H} NMR (CDCl3): 144.24, 144.10, 138.09, 135.65,
135.05, 130.45, 130.27, 129.46, 128.58, 127.92, 127.72, 54.68,
48.66, 48.59, 48.50, 29.50, 22.03; MS m/z (FAB) 893 ([M +
H]+); anal. calcd for C44H52S4O8N4: C, 59.17%; H, 5.87%; N,
6.27%. Found: C, 59.06%; H, 5.63%; N, 6.05%.
1
b, 4H); 13C-{ H} NMR (CDCl3): 142.28, 127.60, 126.31, 125.80,
53.40, 48.27, 47.67; HRMS calcd for C12H19N3 [M]+ 206.1652,
found 206.1654. Ligand L1 has previously been prepared by a
very similar method.29
N,Nꢀ,Nꢀꢀ,NꢀꢀꢀNꢀꢀꢀꢀ -Pentatosyl-2,5,8,11,14-pentaaza[15]meta-
cyclophane (L5–Ts5). By following a procedure similar to
that described for the synthesis of L1–Ts3, N,Nꢀ,Nꢀꢀ,Nꢀꢀꢀ,Nꢀꢀꢀꢀ-
pentatosyl-1,4,7,10,13-pentaazadecatriane (18.16 g, 18.9 mmol),
2,6,10-Triaza[11]metacyclophane (L2). By following a pro-
cedure similar to that described for the synthesis of L3, L2–Ts3
(2.00 g, 2.87 mmol), phenol (4.0 g, 42.50 mmol) and 60 mL of
2 9 4 2
O r g . B i o m o l . C h e m . , 2 0 0 5 , 3 , 2 9 3 5 – 2 9 4 5